Julia Rotow

Julia Rotow

UNVERIFIED PROFILE

Are you Julia Rotow?   Register this Author

Register author
Julia Rotow

Julia Rotow

Publications by authors named "Julia Rotow"

Are you Julia Rotow?   Register this Author

10Publications

213Reads

18Profile Views

Co-occurring alterations in the RAS-MAPK pathway limit response to MET inhibitor treatment in MET exon 14 skipping mutation-positive lung cancer.

Authors:
Julia K Rotow Philippe Gui Wei Wu Victoria M Raymond Richard B Lanman Frederic J Kaye Nir Peled Ferran Fece de la Cruz Brandon Nadres Ryan B Corcoran Iwei Yeh Boris C Bastian Petr Starostik Kimberly Newsom Victor Olivas Alex M Wolff James S Fraser Eric A Collisson Caroline E McCoach D Ross Camidge Jose Pacheco Lyudmila Bazhenova Tianhong Li Trever G Bivona Collin M Blakely

Clin Cancer Res 2019 Sep 23. Epub 2019 Sep 23.

Department of Medicine, Division of Hematology and Oncology, University of California, San Francisco

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-1667DOI Listing
September 2019

A dual pathway inhibition strategy using BKM120 combined with vemurafenib is poorly tolerated in BRAF V600 mutant advanced melanoma.

Authors:
Alain Patrick Algazi Julia Rotow Christian Posch Susana Ortiz-Urda Alyson Pelayo Pamela N Munster Adil Daud

Pigment Cell Melanoma Res 2019 07 13;32(4):603-606. Epub 2019 Apr 13.

UCSF Hematology and Oncology, San Francisco, California.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/pcmr.12777DOI Listing
July 2019

Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.

Authors:
Julia K Rotow Gavitt A Woodard Anatoly Urisman Caroline E McCoach Trever G Bivona Brett M Elicker David M Jablons Collin M Blakely

Clin Lung Cancer 2019 03 20;20(2):e137-e141. Epub 2018 Nov 20.

Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address:

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.cllc.2018.11.003DOI Listing
March 2019

Differential Subcellular Localization Regulates Oncogenic Signaling by ROS1 Kinase Fusion Proteins.

Authors:
Dana S Neel David V Allegakoen Victor Olivas Manasi K Mayekar Golzar Hemmati Nilanjana Chatterjee Collin M Blakely Caroline E McCoach Julia K Rotow Anh Le Niki Karachaliou Rafael Rosell Jonathan W Riess Robert Nichols Robert C Doebele Trever G Bivona

Cancer Res 2019 02 11;79(3):546-556. Epub 2018 Dec 11.

Department of Medicine, University of California at San Francisco, San Francisco, California.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1158/0008-5472.CAN-18-1492DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6359944PMC
February 2019

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer.

Authors:
Khyati N Shah Roma Bhatt Julia Rotow Julia Rohrberg Victor Olivas Victoria E Wang Golzar Hemmati Maria M Martins Ashley Maynard Jonathan Kuhn Jacqueline Galeas Hayley J Donnella Swati Kaushik Angel Ku Sophie Dumont Gregor Krings Henry J Haringsma Liliane Robillard Andrew D Simmons Thomas C Harding Frank McCormick Andrei Goga Collin M Blakely Trever G Bivona Sourav Bandyopadhyay

Nat Med 2019 01 26;25(1):111-118. Epub 2018 Nov 26.

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, San Francisco, CA, USA.

View Article

Download full-text PDF

 Source
http://www.nature.com/articles/s41591-018-0264-7
Publisher Site
http://dx.doi.org/10.1038/s41591-018-0264-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324945PMC
January 2019

Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers.

Authors:
Collin M Blakely Thomas B K Watkins Wei Wu Beatrice Gini Jacob J Chabon Caroline E McCoach Nicholas McGranahan Gareth A Wilson Nicolai J Birkbak Victor R Olivas Julia Rotow Ashley Maynard Victoria Wang Matthew A Gubens Kimberly C Banks Richard B Lanman Aleah F Caulin John St John Anibal R Cordero Petros Giannikopoulos Andrew D Simmons Philip C Mack David R Gandara Hatim Husain Robert C Doebele Jonathan W Riess Maximilian Diehn Charles Swanton Trever G Bivona

Nat Genet 2017 Dec 6;49(12):1693-1704. Epub 2017 Nov 6.

Department of Medicine, University of California, San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

 Source
http://www.nature.com/doifinder/10.1038/ng.3990
Publisher Site
http://dx.doi.org/10.1038/ng.3990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709185PMC
December 2017

Understanding and targeting resistance mechanisms in NSCLC.

Authors:
Julia Rotow Trever G Bivona

Nat Rev Cancer 2017 10;17(11):637-658

Department of Medicine, Division of Hematology and Oncology, University of California San Francisco, 505 Parnassus Avenue, Box 1270, San Francisco, California 94143, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1038/nrc.2017.84DOI Listing
October 2017

Pharmacokinetics, clinical indications, and resistance mechanisms in molecular targeted therapies in cancer.

Authors:
Benjamin Izar Julia Rotow Justin Gainor Jeffrey Clark Bruce Chabner

Pharmacol Rev 2013 3;65(4):1351-95. Epub 2013 Oct 3.

10 North Grove Street, LRH 214, Boston, MA, 02114.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1124/pr.113.007807DOI Listing
February 2014

RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis.

Authors:
Juliana J Oh Eileen O Taschereau Ashley K Koegel Charles L Ginther Julia K Rotow Khadijeh Z Isfahani Dennis J Slamon

Lung Cancer 2010 Dec 24;70(3):253-62. Epub 2010 Mar 24.

Division of Hematology/Oncology, University of California at Los Angeles School of Medicine, 10833 Le Conte Avenue, Los Angeles, CA 90095, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1016/j.lungcan.2010.02.012DOI Listing
December 2010

Vaccines as monotherapy and in combination therapy for prostate cancer.

Authors:
Julia Rotow Sofia R Gameiro Ravi A Madan James L Gulley Jeffrey Schlom James W Hodge

Clin Transl Sci 2010 Jun;3(3):116-22

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

View Article

Download full-text PDF

 Source
http://dx.doi.org/10.1111/j.1752-8062.2010.00186.xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2914613PMC
June 2010